These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23229421)

  • 1. The vagina as a route for drug delivery: a review.
    Srikrishna S; Cardozo L
    Int Urogynecol J; 2013 Apr; 24(4):537-43. PubMed ID: 23229421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why consider vaginal drug administration?
    Alexander NJ; Baker E; Kaptein M; Karck U; Miller L; Zampaglione E
    Fertil Steril; 2004 Jul; 82(1):1-12. PubMed ID: 15236978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vagina as a route for systemic drug delivery.
    Hussain A; Ahsan F
    J Control Release; 2005 Mar; 103(2):301-13. PubMed ID: 15763615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.
    Hartigan SM; Dmochowski RR
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):103-110. PubMed ID: 31918590
    [No Abstract]   [Full Text] [Related]  

  • 8. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
    Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
    Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL; Wein AJ
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.
    Oefelein MG
    Drug Saf; 2011 Sep; 34(9):733-54. PubMed ID: 21830836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?
    Marcelissen T; Rashid T; Antunes Lopes T; Delongchamps NB; Geavlete B; Rieken M; Cornu JN; Rahnama'i MS;
    Eur Urol Focus; 2019 Nov; 5(6):1112-1119. PubMed ID: 29625926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.
    Zacche MM; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1365-74. PubMed ID: 24899225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.